Company news

Tempest Therapeutics, Inc. news in 2026

Tempest Therapeutics, Inc.'s news releases, calls and decks from 2026, newest first.

View company

Tempest Appoints John W. Frederick to Board of Directors, Strengthening Financial and Capital Markets Expertise

October 14, 2026

Tempest Appoints Global Finance Leader Nancy Freda-Smith to Board of Directors

September 23, 2026

Tempest Therapeutics Announces Up to $7.5 Million Private Placement

September 11, 2026

Tempest to Present at the H.C. Wainwright 28th Annual Global Investment Conference

September 8, 2026

Tempest Reports Second Quarter 2026 Financial Results and Provides Business Update

August 13, 2026

Tempest Announces Development Collaboration with Senlang Biotechnology for TPST-4003, a CD7-Targeted Next-Generation In Vivo CAR-T

July 21, 2026

Tempest Unveils Next-Generation In Vivo CAR-T Pipeline, with First Clinical Study Planned for the Fourth Quarter of 2026

July 15, 2026

Tempest Therapeutics Appoints Drake Richey and John Yee, MD, MPH to Board of Directors

June 4, 2026

Tempest Therapeutics Announces Warrant Exercise for Approximately $2 Million in Gross Proceeds

May 29, 2026

Tempest Reports First Quarter 2026 Financial Results and Provides Business Update

May 14, 2026

Tempest Presents Clinical Update at ISCT 2026 Annual Meeting

May 6, 2026

Tempest to Advance Dual-Targeting CAR-T Platform with Clinical Update at ISCT 2026 Annual Meeting

April 29, 2026

Tempest Announces Key Manufacturing Milestone for TPST-2003 Dual-Targeting CD19/BCMA CAR-T

April 21, 2026

Tempest Appoints Andrew Fang, Ph.D., as Head of Business Development to Advance Strategic Partnerships and Global Licensing Efforts

April 13, 2026

Tempest Reports Year End 2025 Financial Results and Provides Business Update

March 29, 2026

Tempest Therapeutics Announces Up To $6 Million Private Placement

March 23, 2026

Tempest Announces Partnership for TPST-2003 in Preparation for Planned U.S. Registrational Study in 2026

March 10, 2026

Tempest Announces Interim Results from Ongoing REDEEM-1 Trial of TPST-2003, Preparing for Potential U.S. Registrational Study in 2026

February 24, 2026

Tempest Lays Out Strategic Plan to Advance Recently Acquired Dual-Targeting CAR-T Assets

February 11, 2026

Tempest Announces Closing of Strategic Acquisition of Dual-Targeting CAR-T Assets

February 4, 2026

Tempest Announces Record Date for Anticipated Dividend Distribution of Warrants to Stockholders

January 20, 2026

Decks in 2026